Existing Account

Please login first to complete purchase/ quotation request, view custom order reports, or create favorites list.

Customer ID:
Stay Logged In

Forgot your Customer ID or Password?
New Account

Don't have an account with us yet? Please set up an account to place order or obtain customer services.

Assay Kits  >  MMP Assay Kits  >>  SensoLyte ® 520 MMP-9 Assay Kit *Fluorimetric*

Product Name SensoLyte ® 520 MMP - 9 Assay Kit *Fluorimetric*
Size 1 kit
Catalog # AS-71155
US$ $457

MMP-9 (gelatinase-B, collagenase-IV) is involved in quite a few diseases such as a cancer, angiogenesis, alopecia and metastasis. The SensoLyte® 520 MMP-9 Assay Kit uses a 5-FAM (fluorophore) and QXL520™ (quencher) labeled FRET peptide substrates for continuous measurement of the enzyme activities. In an intact FRETpeptide, the fluorescence of 5-FAM is quenched by QXL520™. Upon the cleavage of the FRET peptide by MMP-9, the fluorescence of 5-FAM is recovered, and can be continuously monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, 5-FAM/QXL520™ based FRET peptide is less interfered by the autofluorescence of test compounds and cellular components and provides better assay sensitivity. The assays are performed in a convenient 96-well or 384-well microplate format. Members of the MMP family have poor substrate sequence specificity, making it difficult to use a peptide substrate alone to differentiate the activity of a particular MMP from other MMPs. If several MMPs are coexisting in your samples and you would like to specifically measure MMP-9 activity, please choose the SensoLyte® Plus MMP-9 Assay Kit, Cat# 72017.

Kit size:100 assays

Detailed Information Datasheet
Material Safety Data Sheets (MSDS)
Storage -20°C
Product Citations Kalafatovic D, et al. (2016). MMP-9 triggered self-assembly of doxorubicin nanofiber depots halts tumor growth. Biomaterials, 98, 192-202. https://doi.org/10.1016/j.biomaterials.2016.04.039

Pifer, MA. et al. (2014). Matrix metalloproteinase content and activity in low-platelet, low-leukocyte and high-platelet, high-leukocyte platelet rich plasma (PRP) and the biologic response to PRP by human ligament fibroblasts. Am J Sports Med 42, 1122. doi: 10.1177/0363546514524710.

Spolidoro, M. et al. (2013). Inhibition of matrix metalloproteinases prevents the potentiation of nondeprived-eye responses after monocular deprivation in juvenile rats. Cereb Cortex 22, 725. doi: 10.1093/cercor/bhr158.

Inoue, H. et al. (2012). Association of the MMP9 gene with childhood cedar pollen sensitization and pollinosis. J Hum Genet., 57, 176.

Wigner, NA. et al. (2011). Urine matrix metalloproteinases (MMPSs) as biomarkers for the progression of fracture healing. Injury 10.1016/j.injury.2011.05.038.

Koyama, Y. et al. (2010). Intracerebroventricular administration of an endothelin ETB-receptor agonist increases expression of matrix metalloproteinase-2 and -9 in rat brain. J Pharmacol Sci 114, 433.

Yuan, H. et al. (2010). A novel pharmacophore model for the design of anthrax lethal factor inhibitors. Chem Biol Drug Design 76, 263.

Allington, T. et al. (2009). Activated Abl kinase inhibits oncogenic transforming growth factor-β signaling and tumorigenesis in mammary tumors. FASEB J, 23, 4231-4243.

Johnson, SL. et al. (2008). Rhodamine derivatives as selective protease inhibitors against bacterial toxins. Chem Biol Drug Des 71, 131.

Soehnlein, O. et al. (2008). Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. ERJ 32, 405.

Johnson, SL. et al. (2007). A high-throughput screening approach to anthrax lethal factor inhibition. Bioorg Chem 35, 306.
  < Back